TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma

BACKGROUND: Adoptive cellular therapies with chimeric antigen receptor T cells have revolutionized the treatment of some malignancies but have shown limited efficacy in solid tumors such as glioblastoma and face a scarcity of safe therapeutic targets. As an alternative, T cell receptor (TCR)–enginee...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaettler, Maximilian O, Desai, Rupen, Wang, Anthony Z, Livingstone, Alexandra J, Kobayashi, Dale K, Coxon, Andrew T, Bowman-Kirigin, Jay A, Liu, Connor J, Li, Mao, Bender, Diane E, White, Michael J, Kranz, David M, Johanns, Tanner M, Dunn, Gavin P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944319/
https://www.ncbi.nlm.nih.gov/pubmed/36808076
http://dx.doi.org/10.1136/jitc-2022-006121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944319/
https://www.ncbi.nlm.nih.gov/pubmed/36808076
http://dx.doi.org/10.1136/jitc-2022-006121

Ejemplares similares